MAFB enhances oncogenic Notch signaling in T cell acute lymphoblastic leukemia

• Published in: Science signaling Vol. 10; no. 505
• Main Authors: Pajcini, Kostandin V, Xu, Lanwei, Shao, Lijian, Petrovic, Jelena, Palasiewicz, Karol, Ohtani, Yumi, Bailis, Will, Lee, Curtis, Wertheim, Gerald B, Mani, Rajeswaran, Muthusamy, Natarajan, Li, Yunlei, Meijerink, Jules P P, Blacklow, Stephen C, Faryabi, Robert B, Cherry, Sara, Pear, Warren S
• Format: Journal Article
• Language: English
• Published: United States 14.11.2017
• ISSN: 1937-9145
• DOI: 10.1126/scisignal.aam6846

Activating mutations in the gene encoding the cell-cell contact signaling protein Notch1 are common in human T cell acute lymphoblastic leukemias (T-ALLs). However, expressing mutant alleles in mice fails to efficiently induce the development of leukemia. We performed a gain-of-function screen to identify proteins that enhanced signaling by leukemia-associated Notch1 mutants. The transcription factors MAFB and ETS2 emerged as candidates that individually enhanced Notch1 signaling, and when coexpressed, they synergistically increased signaling to an extent similar to that induced by core components of the Notch transcriptional complex. In mouse models of T-ALL, MAFB enhanced leukemogenesis by the naturally occurring Notch1 mutants, decreased disease latency, and increased disease penetrance. Decreasing MAFB abundance in mouse and human T-ALL cells reduced the expression of Notch1 target genes, including and , and sustained MAFB knockdown impaired T-ALL growth in a competitive setting. MAFB bound to ETS2 and interacted with the acetyltransferases PCAF and P300, highlighting its importance in recruiting coactivators that enhance Notch1 signaling. Together, these data identify a mechanism for enhancing the oncogenic potential of weak Notch1 mutants in leukemia models, and they reveal the MAFB-ETS2 transcriptional axis as a potential therapeutic target in T-ALL.